FDA and FTC warn Metamune over DiabetesSupport supplement claims to treat diabetes without approval.
What happened
In August 2021, FDA reviewed Metamune's website, Facebook page, and Amazon storefront and found claims that DiabetesSupport treats, prevents, or helps control diabetes. FDA said those claims make the dietary supplement an unapproved new drug and a misbranded drug because it lacks adequate directions for use. FTC also reviewed the sites and demanded that the company stop making diabetes claims unless it has competent and reliable scientific evidence.
What FDA found
The website, Facebook, and Amazon claims show DiabetesSupport is intended to treat, prevent, or control diabetes, which makes it a drug under the Act.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]DiabetesSupport is not generally recognized as safe and effective for those uses, so it is a new drug.
section 201(p) of the Act [21 U.S.C. 321(p)]The company introduced or delivered the unapproved new drug into interstate commerce without FDA approval.
sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]DiabetesSupport is misbranded because it lacks adequate directions for use by a layperson for its intended disease uses.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5The company introduced or delivered the misbranded drug into interstate commerce.
section 301(a) of the Act [21 U.S.C. 331(a)]FTC says the company must stop claiming a product can prevent, treat, or cure diabetes without competent and reliable scientific evidence from well-controlled human studies.
FTC Act, 15 U.S.C. ยง 41 et seq.
What FDA wants
Within 15 working days of receipt, FDA asks Metamune to write to CFSANResponse@fda.hhs.gov with the specific steps it has taken, an explanation of how it will prevent recurrence, and related documentation; if it believes there is no violation, it should send its reasoning and support. The FTC separately asks the company to notify Richard Cleland within 15 working days of actions taken to address FTC's concerns.
Who should pay attention
- dietary supplement brands making diabetes claims
- online sellers and Amazon storefront operators
- marketers of health products on websites and social media
This is a summary. Read the original letter on fda.gov.